CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Clinical Trials
Original article

Eclipsebio expands its RNA characterization capabilities with multi-attribute nanopore-based sequencing assay eSTRAND RNA QC™

eSTRAND RNA QC™Positive
AI Analysis

Summary

Eclipsebio announced the expansion of its RNA characterization capabilities with eSTRAND RNA QC™, a nanopore-based direct RNA sequencing assay for multi-attribute RNA analysis without reverse transcription requirements.

Importance:2/10
Sentiment:
0.30
product launchtechnology platformRNA sequencingnanoporequality control

Read the original article

Published by PR Newswire Clinical Trials on September 1, 2026 1:00 PM

Read Original